BORA PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 745 TWD | -2.10% |
|
-5.34% | +16.59% |
| Sales 2024 * | 17.76B 552M | Sales 2025 * | 20.99B 652M | Capitalization | 75.09B 2.33B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.5B 109M | Net income 2025 * | 4.81B 149M | EV / Sales 2024 * | 4.49 x |
| Net Debt 2024 * | 4.58B 142M | Net Debt 2025 * | 626M 19.45M | EV / Sales 2025 * | 3.61 x |
| P/E ratio 2024 * |
21.6
x | P/E ratio 2025 * |
15.7
x | Employees | - |
| Yield 2024 * |
2.08% | Yield 2025 * |
1.78% | Free-Float | 56.72% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.10% | ||
| 1 week | -5.34% | ||
| Current month | -2.61% | ||
| 1 month | -0.93% | ||
| 3 months | +10.86% | ||
| 6 months | +15.68% | ||
| Current year | +16.59% |
1 week
740.00
799.00
1 month
695.00814.00
Current year
612.00845.00
1 year
534.30845.00
3 years
101.09845.00
5 years
46.63845.00
10 years
10.31845.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pao Hsi Sheng
CEO | Chief Executive Officer | - | 09-10-20 |
Chin Chu Wang
DFI | Director of Finance/CFO | - | 13-04-30 |
Raymond Lee
CTO | Chief Tech/Sci/R&D Officer | - | 18-06-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shang Hung Shen
BRD | Director/Board Member | 65 | 14-08-25 |
Kuan Pai Chen
BRD | Director/Board Member | - | 19-06-10 |
Pao Hsi Sheng
CEO | Chief Executive Officer | - | 09-10-20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +4.71% | - | |
| 0.00% | 34 M€ | +4.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 745 | -2.10% | 2 154 129 |
| 24-05-27 | 761 | +1.20% | 1,468,281 |
| 24-05-24 | 752 | -2.08% | 1,964,971 |
| 24-05-23 | 768 | +0.52% | 3,628,674 |
| 24-05-22 | 764 | -0.39% | 1,497,997 |
End-of-day quote Taiwan S.E., May 27, 2024
More quotes
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
Sector
Pharmaceuticals
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
745
TWD
Average target price
894.4
TWD
Spread / Average Target
+20.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.59% | 2.38B | |
| +37.44% | 727B | |
| -7.89% | 354B | |
| +15.47% | 328B | |
| -0.63% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +3.79% | 164B | |
| -2.15% | 164B |
- Stock Market
- Equities
- 6472 Stock
